CTOs on the Move

CSL Behring

www.cslbehring.com

 
Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger. With operations in more than 30 nations and over 12,000 employees worldwide, we develop and deliver biotherapies to prevent and treat people with life-threatening medical conditions. Our broad-range of therapies include those to treat disorders such as hemophilia and primary immune deficiencies. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research. Our world-class commercial operation, ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Steven Yannelli
Director of Application Security and Compliance Profile

Similar Companies

Innovative Seating

Innovative Seating Solutions manufactures custom-fitted chairs, back orthotics and seat cushions to relieve pain and enhance seating comfort.

Artelon

Artelons technology was developed explicitly to enhance the strength and kinematic demands of reconstructed tendons and ligaments. Artelons Dynamic Matrix restores native motion, resists the necrotic degradation of  strength, and promotes an ideal me...

Cardiology Consultants of Philadelphia

As America’s largest independent cardiac care practice, CCP is home to the most experienced cardiologists in the Philadelphia region.

RW Troxell

RW Troxell is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nektar

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar`s proprietary and proven chemistry platform in the discovery and design of our new drug candidates.